{
    "title": "113_s2813",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``National Prostate Cancer Council \nAct''.\n\nSEC. 2. NATIONAL PROSTATE CANCER COUNCIL.\n\n    (a) Establishment.--There is established in the Office of the \nSecretary of Health and Human Services (referred to in this section as \nthe ``Secretary'') the National Prostate Cancer Council on Screening, \nEarly Detection, Assessment, and Monitoring of Prostate Cancer \n(referred to in this Act as the ``Council'').\n    (b) Purpose of the Council.--The Council shall--\n            (1) develop and implement a national strategic plan for the \n        accelerated creation, advancement, and testing of diagnostic \n        tools to improve screening, early detection, assessment, and \n        monitoring of prostate cancer, including--\n                    (A) early detection of aggressive prostate cancer \n                to save lives;\n                    (B) monitoring of tumor response to treatment, \n                including recurrence and progression; and\n                    (C) accurate assessment and surveillance of \n                indolent disease to reduce unnecessary biopsies and \n                treatment;\n            (2) provide information and coordination of prostate cancer \n        research and services across all Federal agencies;\n            (3) review diagnostic tools and their overall effectiveness \n        at screening, detecting, assessing, and monitoring of prostate \n        cancer;\n            (4) evaluate all programs in prostate cancer that are in \n        existence on the date of enactment of this Act, including \n        Federal budget requests and approvals and public-private \n        partnerships;\n            (5) submit an annual report to the Secretary and Congress \n        on the creation and implementation of the national strategic \n        plan under paragraph (1); and\n            (6) ensure the inclusion of men at high-risk for prostate \n        cancer, including men from ethnic and racial populations and \n        men who are least likely to receive care, in clinical, \n        research, and service efforts, with the purpose of decreasing \n        health disparities.\n    (c) Membership.--\n            (1) Federal members.--The Council shall be led by the \n        Secretary or designee and comprised of the following experts:\n                    (A) Two representatives of the National Institutes \n                of Health, including 1 representative of the National \n                Institute of Biomedical Imaging and Bioengineering and \n                1 representative of the National Cancer Institute.\n                    (B) A representative of the Centers for Disease \n                Control and Prevention.\n                    (C) A representative of the Centers for Medicare \n                and Medicaid Services.\n                    (D) A designee of the Director of the Department of \n                Defense Congressionally Directed Medical Research \n                Program.\n                    (E) A designee of the Director of the Office of \n                Minority Health.\n                    (F) A representative of the Food and Drug \n                Administration.\n                    (G) A representative of the Agency for Healthcare \n                Research and Quality.\n            (2) Non-federal members.--In addition to the members \n        described in paragraph (1), the Council shall include 16 expert \n        members from outside the Federal Government, which shall \n        include at least--\n                    (A) 6 prostate cancer patient advocates, \n                including--\n                            (i) 2 patient-survivors;\n                            (ii) 2 caregivers of prostate cancer \n                        patients; and\n                            (iii) 2 representatives from national \n                        prostate cancer disease organizations that fund \n                        research or have demonstrated experience in \n                        providing assistance to patients, families, and \n                        medical professionals, including information on \n                        health care options, education, and referral; \n                        and\n                    (B) 8 health care stakeholders with specific \n                expertise in prostate cancer research in the critical \n                areas of clinical expertise, including medical \n                oncology, radiology, radiation oncology, urology, and \n                pathology.\n    (d) Meetings.--The Council shall meet quarterly and meetings shall \nbe open to the public.\n    (e) Advice.--The Council shall advise the Secretary, or the \nSecretary's designee.\n    (f) Annual Report.--The Council shall submit annual reports, \nbeginning not later than 1 year after the date of enactment of this \nAct, to the Secretary or the Secretary's designee and to Congress. The \nannual report shall include--\n            (1) in the first year--\n                    (A) an evaluation of all federally funded efforts \n                in prostate cancer research and gaps relating to the \n                development and validation of diagnostic tools for \n                prostate cancer; and\n                    (B) recommendations for priority actions to expand, \n                eliminate, coordinate, or condense programs based on \n                the performance, mission, and purpose of the programs; \n                and\n            (2) annually thereafter for 5 years--\n                    (A) an outline for the development and \n                implementation of a national research plan for creation \n                and validation of accurate diagnostic tools to improve \n                prostate cancer care in accordance with subsection (a);\n                    (B) roles for the National Cancer Institute, \n                National Institute on Minority Health and Health \n                Disparities, and the Office on Minority Health of the \n                Department of Health and Human Services;\n                    (C) an analysis of the disparities in the incidence \n                and mortality rates of prostate cancer in men at high \n                risk of the disease, including individuals with family \n                history, increasing age, or African-American heritage; \n                and\n                    (D) a review of the progress towards the \n                realization of the proposed strategic plan.\n    (g) Termination.--The Council shall terminate on December 31, 2019.\n    (h) Authorization of Appropriations.--There are authorized to be \nappropriated to carry out this section $2,000,000 for the period of \nfiscal years 2015 through 2019."
}